|
 |
CardeneThis page contains recent news articles, when available, and an overview of Cardene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cardene (when available) Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Used for the management of patients with chronic stable angina Mechanism Of Action: By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. News Articles on Nicardipine HIGH KNIGHTON FARM - Dec 14, 2009 Cardene oak effect floor. Extractor fan. Window. High Knighton Farm is approached via a gravel driveway which sweeps around the stables and garages and ... Farming UK Asocian fármacos para la presión con menor riesgo de Parkinson - Dec 24, 2009 ...canales de calcio llamados dihidropiridinas, que incluyen medicamentos como la nifedipina (Adalat), la felodipina (Plendil) y la nicardipina (Cardene). ... Público EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene ... - Oct 28, 2009 Once issued, the patent will cover pharmaceutical formulations of RTU Cardene IV through 2027. Additionally, upon issuance of the patent, EKR will file the ... Reuters Brace from Delvon wins it for SSG STRIKERS - Nov 11, 2009 The first real chance of the game came in the 4th minute for Villa International United, when SSG Strikers defender gave the ball away to Cardene Powell ... The Leewards Times PDL's Sales Top Estimates - Nov 2, 2006 Cardene sales in the most recent quarter included sales of Cardene SR, which the company acquired from Roche in September. Sales of the heart drug Retavase ... TheStreet.com - TheStreet.com (subscription) PDL BioPharma's holder seeks chairman's resignation - Aug 29, 2007 The company is looking for buyers for all of its marketed products, including Cardene, for short-term treatment of acute high blood pressure, and Retavase, ... Reuters EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement … - Feb 4, 2008 PDL and EKR agree that the long-term value of the Cardene franchise can be both ... Cardene IV was approved in the United States by the US Food and Drug ... Lifescience-online PDL BioPharma puts company, or assets, up for sale - Oct 1, 2007 PDL BioPharma last month said it planned to sell off all its marketed medicines, including blood pressure treatment Cardene, and its Retavase treatment for ... Reuters PDL BioPharma Refocuses - Aug 28, 2007 The company's new plan to refocus on cancer and select immunological diseases, involves the sale of its Cardene, Retavase and IV Busulfex products, ... TheStreet.com - TheStreet.com (subscription) Korean War vet receives Medal of Honor 55 years after his heroics - Oct 24, 2005 Also included were the calcium channel blockers Verelan, Verelan PM, Covera HS, Cardizem LA, Norvasc, DynaCirc, DynaCirc CR, Cardene and Cardene SR. ... Providence Journal … Premixed Double Concentration Cardene® IV (nicardipine hydrochlorid... - Dec 10, 2008 EKR's product offerings of Cardene IV RTU bags also include single (1X) concentration ... Both the 2X and 1X Cardene IV RTU Bags support TJC 1 and ASHP 2 ... International Business Times Cardene.(drug overview)(Drug overview) - Dec 1, 2005 Cardene, a type of medication called a calcium channel blocker, is prescribed for the treatment of chronic stable angina (chest pain usually caused by lack ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com PDL BioPharma posts quarterly profit after loss - Aug 1, 2007 Total revenue for the quarter jumped 32 percent to $138 million, fueled by a 66 percent rise in sales if the intravenous blood pressure medicine Cardene to ... Reuters PDL Biopharma 1st-qtr net loss narrows - May 2, 2007 ..."In the first quarter, our three marketed acute-care products, led by our Cardene product, and our antibody platform royalties drove solid revenue growth at ... Reuters EKR Therapeutics Broadens Its Ready-to-Use Cardene(R) IV Product … - Nov 11, 2008 EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that it ... Genetic Engineering News - Genetic Engineering News (press release) Cardene makes big splash in debut for Rancocas Valley - Apr 7, 2006 BURLINGTON TWP. -- For just a second -- one pitch, actually -- Rancocas Valley High School's Seth Cardene looked like a sophomore playing his first varsity ... $3.50 - Burlington County Times - NewsBank PDL BioPharma Completes Sale of Cardiovascular Products to EKR … - Mar 10, 2008 PDL would earn $25 million of the potential milestone payments upon the marketing approval of a new Cardene formulation by the United States Food and Drug ... Lifescience-online Cardene.(Drug overview) - Jan 22, 2007 Cardene, a type of medication called a calcium channel blocker, is prescribed for the treatment of chronic stable angina (chest pain usually caused by lack ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com PDL to Acquire ESP Pharma, Inc. - Final. - Jan 25, 2005 ESP leading product, Cardene IV, is indicated for the short-term treatment of hypertension ... Cardene is a patent-protected IV preparation of Nicardipine, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Roche Gives Up Daclizumab; PDL Seeking Asthma Partner - Nov 27, 2006 PDL gained Cardene in its 2005 acquisition of Edison, NJ-based ESP Pharma Inc., ... "Our cardiology contacts believe that the market for Cardene in acute ... BioWorld Online - BioWorld Online Recurring cluster headaches provide unimaginable pain - Jun 22, 2008 These drugs include nitrates, nitroglycerin and calcium channel blockers like Cardene, Procardia, Norvasc and many others. ... Chattanooga Times Free Press Protein Design Labs Becomes PDL BioPharma. - Jan 9, 2006 The company now markets Cardene(R) IV (nicardipine hydrochloride) for short-term treatment of hypertension when oral therapy is not feasible or desirable, ... Free with registration - PR Newswire - AccessMyLibrary.com EKR Therapeutics Receives Approval for Ready-to-Use Intravenous - Aug 1, 2008 The RTU formulations significantly expand the Cardene franchise which has ... "With the addition of the ready-to-use bags, the breadth of our Cardene ... Bloomberg MEDS BETTER THAN GRAPEFRUIT - Mar 25, 2007 Atorvastatin (Lipitor), lovastatin (Mevacor), simvastatin (Zocor), diltiazem (Cardizem and others), felodipine (Plendil), nicardipine (Cardene), ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver PDL makes inroads in US. - Feb 10, 2005 The acquisition expand PDL's activities into the cardiovascular sector with the intravenous antihypertensive Cardene. The deal has been approved by both ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Protein Design Labs Announces Above Consensus Full-Year and Fourth … - Mar 14, 2005 Product revenues for Cardene IV, Retavase and IV Busulfex are expected to total approximately $93 to $95 million for the anticipated. Free with registration - PR Newswire - AccessMyLibrary.com Q2 2006 PDL BioPharma Earnings Conference Call - Part 1. - Aug 3, 2006 Sales of our three marketed products, Cardene IV, Retavase, ... Cardene IV, our IV anti-hypertensive agent used when oral therapy is not feasible or ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com EKR Therapeutics Appoints Co-Founder Richard DeSimone as COO - Mar 27, 2008 The Company's growing portfolio of specialty acute-care products includes Cardene(R) IV (nicardipine hydrochloride), Cardene SR(R), Retavase(R) (reteplase ... Genetic Engineering News - Genetic Engineering News (press release) Product Licensing; Therapeutics company purchases rights to Retavase - Feb 28, 2005 Acquired from Wyeth (NYSE:WYE) in May 2002, Cardene IV is a patent protected intravenous preparation of nicardipine for treating hypertension. ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones ESP Pharma Acquires Exclusive North American Rights to Retavase, an … - Feb 1, 2005 Acquired from Wyeth (NYSE:WYE) in May 2002, Cardene(R) IV is a patent protected intravenous preparation of nicardipine for treating hypertension. ... $4.95 - Business Wire - ECNext PDL BioPharma Announces Third Quarter 2006 Financial Results. - Nov 2, 2006 ..."During the third quarter, increases in Cardene IV sales and strong partner-driven ... Cardene net sales were $28.7 million in the third quarter of 2006, ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of Q2 2007 PDL BioPharma Earnings Conference Call - Final. - Aug 1, 2007 Growth in product sales continues to be led by Cardene, which ... In 2Q07, due to a reduction in Cardene product returns in recent periods, lowered returns ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Cink og Verplank fik wild card - Aug 21, 2006 ..."De to, der fik wild cardene, er jeg sikker pÃ¥ vil gøre holdet komplet. Stewart har spillet stabilt gennem hele sin karriere. Han rammer bolden flot, ... TV2 Medicines Company Leaves Sour Taste - Feb 15, 2007 When compared with market leader Cardene IV, made by PDL Biopharma (PDLI - commentary - Cramer's Take), Cleviprex had an inferior safety profile. ... TheStreet.com - TheStreet.com (subscription) Article: Protein Design to acquire ESP Pharma. - BIOTECH Patent News... - Jan 1, 2005 Our flagship product, Cardene IV, is indicated for the short-term ... Cardene IV, ESP Pharma's lead product ... annualized sales of Cardene IV have ... Pay-Per-View - BIOTECH Patent News - HighBeam Research PDL BioPharma at Merrill Lynch Global Pharmaceutical, Biotech & … - Sep 22, 2006 And a good chunk of that is the addition of the three products, Cardene, Retavase and Busulfex ... Very recently we announced the acquisition of Cardene SR, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com PDL BioPharma to sell drug rights | Article from Oakland Tribune | … - Feb 6, 2008 EKR Therapeutics will buy Cardene, a treatment approved by the Food and Drug ... EKR also will acquire a new formula of Cardene and another potential drug ... Pay-Per-View - Oakland Tribune - HighBeam Research Protein Design to acquire ESP Pharma. - Jan 1, 2005 Our flagship product, Cardene IV, is indicated for the short-term treatment of ... Cardene is a patent -protected intravenous preparation of nicardipine, ... Free with registration - BIOTECH Patent News - AccessMyLibrary.com Press Release: Incremental Direct Expenditure of Treating Hypertension... - Aug 15, 2006 Article: Syntex introduces Cardene for treating hypertension . ... The efficacy of Cardene SR in treating hypertension was demonstrated in four randomized . ... Pay-Per-View - PR Newswire - HighBeam Research EKR licenses PDL heart drugs in deal worth up to $170M. - Feb 11, 2008 Specifically, PDL would receive a $25.0 million milestone upon the approval of a new formulation of Cardene, which it anticipates will occur "well in ... $9.94 - Pharma Marketletter - Alacra Store Mergers & Acquisitions; Medical laboratory acquires pharmaceutical … - Feb 21, 2005 Our flagship product, Cardene IV, is indicated for the short-term treatment of ... Cardene is a patent-protected intravenous preparation of nicardipine, ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Event Brief of Q4 and Year-End 2006 PDL BioPharma Earnings … - Feb 21, 2007 Impressive growth that PDLI continues to see from Cardene is. reflective of the ongoing efforts of sales force and commercial organization to maximize ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL BioPharma at JPMorgan 25th Annual Healthcare Conference - Final. - Jan 11, 2007 PDL also has a commercial portfolio, which includes Cardene and Retavase, ... If you look at our Cardene and our Busulfex market share, they both grew ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL stops sale, will cut 260 people - Mar 5, 2008 PDL said last month that Cardene and Retavase, ... Under PDL's management, Cardene, Retavase and Busulfex brought in $146.9 million through the first nine ... Bizjournals.com PDL BioPharma at JPMorgan 25th Annual Healthcare Conference - Final. - Jan 1, 2007 PDL also has a commercial portfolio, which includes Cardene and Retavase, ... If you look at our Cardene and our Busulfex market share, they both grew ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com PDL BioPharma Announces Fourth Quarter and Full Year 2005 Financial … - Feb 27, 2006 Net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the quarter ... Of this, net sales of Cardene IV, Retavase and IV Busulfex for the year ... $4.95 - PR Newswire - ECNext Activist shareholders are getting some results - Mar 16, 2008 EKR said last month that it was buying Cardene back for $85 million. "It was incredible to watch that team move the needle at Cardene," Oliva said. ... $2.95 - Philadelphia Inquirer - NewsBank PDL BioPharma Announces First Quarter 2007 Financial Results. - May 2, 2007 ..."In the first quarter, our three marketed acute-care products, led by our Cardene(R) product, and our antibody platform royalties drove solid revenue growth ... $4.95 - PR Newswire - ECNext EKR Therapeutics Announces Management Additions and Promotions, … - Mar 27, 2008 In March 2005, ESP was acquired, along with its lead product Cardene(R) IV, ... "Moreover, they have a hands-on understanding of Cardene IV which recently ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: PDL BioPharma Announces Third Quarter 2006 Financial … - Nov 2, 2006 ..."During the third quarter, increases in Cardene IV sales and strong partner-driven ... *Cardene net sales were $28.7 million in the third quarter of 2006, ... Pay-Per-View - PR Newswire - HighBeam Research Despite losing, local players enjoy North-South game experience - Jul 1, 2008 Another player taking the step was Seth Cardene of Rancocas Valley, ... “It was a great week and I got to hang out with some cool guys,â€? Cardene said. ... phillyBurbs.com PDL BioPharma Announces Second Quarter 2007 Financial Results. - Aug 1, 2007 ..."Strong revenue growth in the second quarter was the result of a solid increase in royalties and continued growth of Cardene(R)," said Mark McDade, ... $4.95 - PR Newswire - ECNext PDL BioPharma at Lehman Brothers 10th Annual Global Healthcare … - Mar 19, 2007 As you can see from that slide, Cardene is the number one driver of growth. This drug has growth significantly from the roughly 45 million prior to our ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q3 2005 Protein Design Earnings Conference Call - Part... - Nov 1, 2005 This is PDLI's second full qtr. of net sales of Cardene IV, ... Net product sales for Cardene, Retavase, and Busulfex as a group totaled approx. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q1 2007 PDL BioPharma Earnings Conference Call - Final. - May 2, 2007 Cardene, our antihypertensive franchise, continues to perform to our expectation. In the first quarter of 2007, net sales of Cardene reached $34.5 million ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL Looks for a Push - Aug 2, 2006 That leaves Cardene. Sales of the hypertension drug have risen for the past two years and may need to carry PDL's entire product line if it can achieve the ... TheStreet.com - TheStreet.com (subscription) PDL's Recent Slump Seen Overly Exaggerated - May 9, 2006 ..."Most notably, Cardene IV loses patent protection in November 2009, and the US Queen patents expire in 2014." The Queen patents refer to PDL's antibody ... Forbes FDA OKs Medicines Co.'s Cleviprex - Aug 4, 2008 Amin says the approval of Teva's (TEVA Quote) nicardipine, which is similar to Cardene, also could add pricing pressure. Thus the analyst sees Cleviprex's ... TheStreet.com - TheStreet.com (subscription) Speak with other shareholders about: (NASDAQ: ACAP), (OTCBB: NILR), … - Mar 10, 2008 ...consisting of Cardene IV (nicardipine hydrochloride), Cardene SR and new formulations of Cardene in development, as well as Retavase (reteplase) and the ... Free with registration - M2 Presswire - AccessMyLibrary.com PDL BioPharma swings into 2nd-qtr profit.(Financial report) - Aug 13, 2007 Cardene, which is licensed by biotechnology major Genentech, contributed royalties of $79.8 million, up 48%. Overall, revenues increased 25% to $49.0 ... Free with registration - Pharma Marketletter - AccessMyLibrary.com PDL BioPharma Announces First Quarter 2006 Financial Results. - May 2, 2006 Net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the 2006 first quarter ... The largest component of product sales continues to be Cardene IV. ... $4.95 - PR Newswire - ECNext PDL Announces Third Quarter 2005 Financial Results. - Nov 1, 2005 Of this, net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the quarter totaled approximately $38.0 million, while net sales of the four ... Free with registration - PR Newswire - AccessMyLibrary.com PDL BioPharma Announces Third Quarter 2007 Financial Results. - Nov 8, 2007 ...included a $5.6 million charge incurred in connection with the company's acquisition in September 2006 of certain Cardene-related rights from Roche. ... Free with registration - PR Newswire - AccessMyLibrary.com PDL BioPharma Announces Second Quarter 2006 Financial Results. - Aug 3, 2006 Cardene IV sales were $24.4 million in the second quarter of 2006, a 47 percent increase from $16.7 million for the same period in 2005. ... Free with registration - PR Newswire - AccessMyLibrary.com Caldwell: An update on Veterans' benefits - Dec 7, 2005 The calcium channel blockers Covera HS, Cardizem LA, Novasc, DynaCir CR, Cardene and Cardene SR, Norvasc, Verelan and Verelan PM. ... wickedlocal.com Third Point Urges PDL BioPharma to Cut Costs. - Mar 5, 2007 Moreover, Cardene, which represents close to 60% of the combined $165M revenue stream from the three products, will go generic in 2009. ... Free with registration - PR Newswire - AccessMyLibrary.com PDL BioPharma Reports First Quarter 2008 Financial Results - May 8, 2008 On March 31, PDL submitted a post-approval study for a new Cardene formulation to the US FDA. Under the terms of the asset purchase agreement with EKR ... marketwire.com Q1 2006 PDL BioPharma Earnings Conference Call - Part 2. - May 2, 2006 In the case of Cardene, the step down in the rate is significant. As a result, we expect our Q1 gross margin percentage of 66%, to be the lowest in any ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com URGENT Study Provides Important New Insight into the Use of Dyspnea … - Jul 16, 2008 The Company's growing portfolio of specialty acute-care products includes Cardene(R) IV (nicardipine hydrochloride), Cardene SR(R), Retavase(R) (reteplase ... Genetic Engineering News - Genetic Engineering News (press release) PDL BioPharma Business Update - Part 2. - May 5, 2006 And then you can also use Nicardipine, Cardene, in IV drip. ... Cardene, (indiscernible) and calcium channel blocker, works in minutes. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of PDL BioPharma Strategic Update - Final. - Aug 28, 2007 Cardene. 2. Retavase. 3. IV Busulfex. 4. Ularitide cardiovascular development program. 8. Engaged Merrill Lynch to conduct the sale process in Co. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Q3 2006 PDL BioPharma Earnings Conference Call - Part 3. - Nov 2, 2006 ...is sustainable -- not only sustainable but may grow with growth in sales of Cardene and the contribution to our overall portfolio mix and make it clear ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Centocor, Inc. ESP acquires US, Canadian rights to Retavase, an IV … - Mar 2, 2005 Acquired from Wyeth (WYE) in May 2002, Cardene IV is a patent-protected intravenous preparation of nicardipine for treating hypertension. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Product Licensing; Therapeutics company purchases rights to Retavase - Mar 6, 2005 Acquired from Wyeth (NYSE:WYE) in May 2002, Cardene IV is a patent protected intravenous preparation of nicardipine for treating hypertension. ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Merger and Acquisition Scenario - May 17, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 6, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 16, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 12, 2007 In September 2006, the Company completed the acquisition of various Cardene product-related rights from Roche to solidify its Cardene brand franchise in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 30, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 6, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 29, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 23, 2008 In September 2006, the Company completed the acquisition of various Cardene product-related rights from Roche to solidify its Cardene brand franchise in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 15, 2007 In September 2006, the Company completed the acquisition of various Cardene product-related rights from Roche to solidify its Cardene brand franchise in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 23, 2008 In September 2006, the Company completed the acquisition of various Cardene product-related rights from Roche to solidify its Cardene brand franchise in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 18, 2008 However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR. ... $250.00 - Revere Reports - Revere Brand Names/Synonyms: Cardene is also known by the following brand names and/or synonymsCardene; Cardene Sr; Nicardipine; Nicardipine Hcl; Nicardipino [Inn-Spanish]; Nicardipinum [Inn-Latin]; YC-93 Drug Category: Cardene is categorized under the following by the FDA: Antiarrhythmic Agents; Vasodilator Agents; Antihypertensive Agents; Dihydropyridines; ATC:C08CA04 Dosage Forms: CAPSULE Absorption: While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: methyl2-(benzyl-methyl-amino)ethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |